The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

Vancomycin appeared to top placebo for lowering Clostridioides difficile infection (CDI) recurrence rates in patients taking ...

Fecal microbiota transplantation was not inferior to vancomycin for the treatment of primary Clostridioides difficile ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, ...

Vancomycin, a glycopeptide antibiotic, is commonly used to treat gram-positive pathogens associated with vascular-access-related infections, such as coagulase negative Staphylococcus species, ...

The addition of vancomycin to beta-lactam prophylaxis in arthroplasty may reduce surgical-site infections; however, the efficacy and safety are unclear.In this multicenter, double-blind, superiorit ...

Vancomycin remains one of the most widely used antibiotics for the treatment of Staphylococcus (including methicillin-resistant Staphylococcus aureus), Streptococcus, and Enterococcus infections.

Vancomycin Hydrochloride for Injection had a market value of approximately $39.3 million for the 12 month period ending January 2025, per IQVIA. [Read more: Glenmark releases generic Travatan Z] ...

Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin’s clinical durability. PLOS Pathogens , 2024; 20 (8): e1012422 DOI ...